John Laird, M.D.

John R. Laird, M.D.



Cardiovascular Medicine

Internal Medicine

Interventional Cardiology

Vascular and Endovascular Care


Internal Medicine


  • Medical Director, UC Davis Vascular Center
  • Professor of Medicine
To see if John R. Laird is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

Lawrence J. Ellison Ambulatory Care Center

4860 Y St., Suite 2820
Sacramento, CA 95817
Driving Directions

Primary Phone:

4860 Y St., Suite 2100
Sacramento, CA 95817
Driving Directions

Primary Phone:

Additional Phone Numbers

Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Philosophy of Care

To provide comprehensive cardiovascular care including preventative approaches, optimal medical care and state of the art, minimally invasive therapies.

Clinical Interests

Dr. Laird is an internationally renowned interventional cardiologist who has lectured and performed endovascular procedures around the world. He has also been a leader in the development of Drug Coated Balloon for peripheral artery disease.

His practice focuses on interventions for carotid artery disease, abdominal and thoracic aortic aneurysmal disease, renal artery disease and peripheral artery disease. Among his many areas of leadership and innovation are the investigation of new stents for carotid and peripheral vascular applications and the development of laser angioplasty.

He uses the Excimer laser as a tool for complex peripheral interventions and in limb salvage situations. Dr. Laird is known for innovation, teaching vascular interventions to other physicians, and his role in organizing and conducting clinical trials of new therapies for vascular disease.

Research/Academic Interests

Dr. Laird's research interests include:

1-Innovative approaches to the treatment of peripheral artery disease including new stent designs, drug eluting stents, and drug coated balloons.

2-Stent grafts for abdominal and thoracic aneurysms.

3-Stem cell therapies for advanced peripheral artery disease.

4-New stents for carotid artery disease.


Cardiovascular Medicine

Center/Program Affiliation

Cardiovascular Services


M.D., Albany Medical College, Albany NY 1984


Madigan Army Medical Center, Tacoma WA 1987


Walter Reed Army Medical Center, Washington DC 1990

Board Certifications

American Board of Internal Medicine, 1987

American Board of Internal Medicine, Cardiovascular Disease, 1989

American Board of Internal Medicine, Interventional Cardiology, 1999

Professional Memberships

American College of Cardiology

American College of Physicians

American Heart Association

International Society of Endovascular Specialists

Society for Cardiac Angiography and Interventions

Honors and Awards

LIVE (Leader in Vascular Education) Award, VIVA, 2013

Select Recent Publications

Laird JR, Schneider PA, Tepe G, Brodmann M, Zeller T, Metzger C, Krishnan P, Scheinert D, Micari A, Cohen D, Wang H, Hasenbank MS, Jaff MR, for the IN.PACT SFA Trial Investigators. Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions. 24-Month Results of IN.PACT SFA. J Am Coll Cardiol. 2015 Dec 1;66(21): 2329-38.

Laird JR, Singh GD. Drug Coated Balloons as the New Standard of Care for Femoropopliteal In-Stent Restenosis: Fair Assumption? Circulation. J of the Am Heart Assoc. 2015 Dec 8;132(23):2198-200.

Armstrong EJ, Thiruvoipati T, Tanganyika K, Singh GD, Laird JR. Laser Atherectomy for Treatment of Femoropopliteal In-Stent Restenosis. J of Endovasc Ther. 2015 Aug;22(4):506-513.

Armstrong EJ, Chen DC, Singh GD, Amsterdam EZ, Laird JR. Angiotensis-Converting Enzyme Inhibitors are Associated with Reduced Major Adverse Cardiovascular Events Among Patients with Critical Limb Ischemia. Vasc Med. 2015 Jun;20(3):237-44.

Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, Metzger C, Scheinert D, Zeller T, Cohen DJ, Snead DB, Alexander B, Landini M, Jaff MR. Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Artery Disease: 12-Month Results from the IN.PACT SFA Randomized Trial. Circulation. 2015 Feb 3;131(5):495-502.

Laird JR, Armstrong EJ. Drug Coated Balloons for Infrapopliteal Disease: Digging Deep to Understand the Impact of a Negative Trial. J Am Coll Cardiol. 2014 Oct 14;64(15):1577-9.

Armstrong EJ, Wu J, Singh GD, Ware K, Dawson DL, Pevec WC, Amsterdam EA, Laird JR. Smoking Cessation is Associated With Decreased Mortality and Improved Amputation- Free Survival Among Patients with Symptomatic Peripheral Artery Disease. J Vasc Surg. 2014 Dec;60(6):1565-1571.

Singh S, Armstrong EJ, Sherif W, Alvandi B, Westin GG, Singh GD, Amsterdam EA, Laird JR. Association of Elevated Fasting Glucose with Restenosis and Major Adverse Limb Events Among Patients with Diabetes Undergoing Infrapopliteal Balloon Angioplasty. Vasc Med. 2014 Jun 17;19(4):307-314.

Armstrong EJ, Laird JR. Treatment of Femoropopliteal In-Stent Restenosis for Patients with Diabetes: Do We Have an Answer to the DEBATE? J Endovasc Ther. 2014 Feb;21(1):9-11.

Laird JR, Jain A, Zeller T, Feldman R, Scheinert D, Popma JJ, Armstrong EJ, Jaff MR. Nitinol Stent Implantation in the Superficial Femoral Artery and Proximal Popliteal Artery: 12 Month Results From the Complete SE Trial. J Endovasc Ther. 2014 Apr;21(2):202-12.